Biotech Values

[Bickema]

MNTA's stock price seems to be reacting negatively to this guidance. Is this a general misunderstanding by investors who do not fully grasp MNTA's biosim capabilities in your opinion?

Would a good way to put this in Lehman's terms be that the bar is higher but the pay off is higher and that in theory this will weed out MNTA's weak competitors while solidifying their strong IP?